S&P Removes Valeant Pharma (VRX) from CreditWatch Positive; Ratings Affirmed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
UPDATE: Valeant's (VRX) Plaque Psoriasis Injection Faces July 19th FDA Panel
June 9, 2016 9:14 AM EDT(Updated - June 9, 2016 9:19 AM EDT)
Valeant Pharma's (NYSE: VRX) plaque psoriasis injection faces July 19th FDA panel, according to Bloomberg.
UPDATE - The HHS document is embedded below:
... More